These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 29608845)

  • 21. PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer.
    Adekiya TA; Hudson T; Bakare O; Ameyaw EE; Adebayo A; Olajubutu O; Adesina SK
    Biomed Pharmacother; 2024 Aug; 177():117125. PubMed ID: 39002444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
    Kularatne SA; Venkatesh C; Santhapuram HK; Wang K; Vaitilingam B; Henne WA; Low PS
    J Med Chem; 2010 Nov; 53(21):7767-77. PubMed ID: 20936874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer.
    Derks YHW; Rijpkema M; Amatdjais-Groenen HIV; Kip A; Franssen GM; Sedelaar JPM; Somford DM; Simons M; Laverman P; Gotthardt M; Löwik DWPM; Lütje S; Heskamp S
    Theranostics; 2021; 11(4):1527-1541. PubMed ID: 33408764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates.
    Machulkin AE; Skvortsov DA; Ivanenkov YA; Ber AP; Kavalchuk MV; Aladinskaya AV; Uspenskaya AA; Shafikov RR; Plotnikova EA; Yakubovskaya RI; Nimenko EA; Zyk NU; Beloglazkina EK; Zyk NV; Koteliansky VE; Majouga AG
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2229-2235. PubMed ID: 31248772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
    Wang S; Blaha C; Santos R; Huynh T; Hayes TR; Beckford-Vera DR; Blecha JE; Hong AS; Fogarty M; Hope TA; Raleigh DR; Wilson DM; Evans MJ; VanBrocklin HF; Ozawa T; Flavell RR
    Mol Pharm; 2019 Sep; 16(9):3831-3841. PubMed ID: 31381351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
    Huang B; Otis J; Joice M; Kotlyar A; Thomas TP
    Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic.
    Pearce AK; Simpson JD; Fletcher NL; Houston ZH; Fuchs AV; Russell PJ; Whittaker AK; Thurecht KJ
    Biomaterials; 2017 Oct; 141():330-339. PubMed ID: 28711780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PSMA Antibody-Conjugated Pentablock Copolymer Nanomicellar Formulation for Targeted Delivery to Prostate Cancer.
    Owiti AO; Pal D; Mitra A
    AAPS PharmSciTech; 2018 Nov; 19(8):3534-3549. PubMed ID: 30151731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a PSMA-targeted BNF nanoparticle construct.
    Behnam Azad B; Banerjee SR; Pullambhatla M; Lacerda S; Foss CA; Wang Y; Ivkov R; Pomper MG
    Nanoscale; 2015 Mar; 7(10):4432-42. PubMed ID: 25675333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-delivery of Siape1 and Melatonin by
    Liu Y; Hao L; Dong Y; Dong BZ; Wang XL; Liu X; Hu ZX; Fang GC; Wang GY; Qin JX; Shi ZD; Pang K
    Recent Pat Anticancer Drug Discov; 2024; 19(4):503-515. PubMed ID: 39044710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PSMA-Targeted 2-Deoxyglucose-Based Dendrimer Nanomedicine for the Treatment of Prostate Cancer.
    Rani A; Pulukuri AJ; Wei J; Dhull A; Dar AI; Sharma R; Mesbahi N; Savoy EA; Yoon H; Wu BJ; Berkman CE; Sharma A
    Biomacromolecules; 2024 Sep; 25(9):6164-6180. PubMed ID: 39164913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer.
    Rosenfeld L; Sananes A; Zur Y; Cohen S; Dhara K; Gelkop S; Ben Zeev E; Shahar A; Lobel L; Akabayov B; Arbely E; Papo N
    J Med Chem; 2020 Jul; 63(14):7601-7615. PubMed ID: 32442375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cell-impermeable luminogenic probe for near-infrared imaging of prostate-specific membrane antigen in prostate cancer microenvironments.
    Yang X; Nao SC; Lin C; Kong L; Wang J; Ko CN; Liu J; Ma DL; Leung CH; Wang W
    Eur J Med Chem; 2023 Nov; 259():115659. PubMed ID: 37499288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical Evaluation of
    Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
    J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer.
    Schatz CA; Zitzmann-Kolbe S; Moen I; Klotz M; Nair S; Stargard S; Bjerke RM; Wickstrøm Biseth K; Feng YZ; Indrevoll B; Cruciani V; Karlsson J; Haendler B; Nielsen CH; Alfsen MZ; Hammer S; Hennekes H; Cuthbertson A; Hagemann UB; Larsen Å
    Clin Cancer Res; 2024 Jun; 30(11):2531-2544. PubMed ID: 38593212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
    Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
    Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation.
    Lesniak WG; Boinapally S; Lofland G; Jiang Z; Foss CA; Behman Azad B; Jablonska A; Garcia MA; Brzezinski M; Pomper MG
    Int J Nanomedicine; 2024; 19():4995-5010. PubMed ID: 38832336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.